openPR Logo
Press release

Natural Killer Cell Therapies Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, C

02-10-2025 05:03 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Natural Killer Cell Therapies Pipeline Insights

Natural Killer Cell Therapies Pipeline Insights

Natural Killer Cell Therapies Pipeline constitutes 100+ key companies continuously working towards developing 140+ Natural Killer Cell Therapies treatment therapies, analyzes DelveInsight.

Natural Killer Cell Therapies Overview:

Natural killer (NK) cells are a type of lymphocyte and a crucial component of the innate immune system. They act as specialized predators, playing a vital role in the body's defense against tumors and virus-infected cells. In cancer patients, various NK cell abnormalities have been identified, including reduced cytotoxicity, impaired activation receptor expression, altered intracellular signaling, excessive inhibitory receptor expression, defective proliferation, and diminished presence in both peripheral blood and tumor tissue, along with impaired cytokine production.

NK cell therapy has shown the most success in treating hematologic malignancies like leukemia. This immunotherapy approach can either enhance the body's natural NK cell response through stimulatory agents or introduce external NK cells via hematopoietic stem cell transplantation (HSCT) or adoptive cell transfer. Several strategies for NK cell-based immunotherapy in cancer treatment have been proposed, utilizing different methods to optimize their therapeutic potential.
Request for a detailed insights report on Natural Killer Cell Therapies pipeline insights @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Natural Killer Cell Therapies Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Natural Killer Cell Therapies Therapeutics Market.

Key Takeaways from the Natural Killer Cell Therapies Pipeline Report

DelveInsight's Natural Killer Cell Therapies pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer Cell Therapies treatment.
In October 2024, ImmunityBio announced that the first patients had received doses in an initial trial evaluating the potential of its CAR-NK cell therapy targeting CD-19 for the treatment of non-Hodgkin's lymphoma (NHL).
In July 2024, the U.S. Food and Drug Administration (FDA) granted Nkarta approval to initiate a clinical trial for its cell therapy candidate, NKX019, in patients with ANCA-associated vasculitis (AAV) and other autoimmune disorders.
In May 2024, KGen Biotech reported that its Safety Review Committee had approved the advancement of the company's cryopreserved autologous, expanded, and enhanced SNK01 into Phase II clinical development.
Key Natural Killer Cell Therapies companies such as ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others are evaluating new drugs for Natural Killer Cell Therapies to improve the treatment landscape.
Promising Natural Killer Cell Therapies pipeline therapies in various stages of development include Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others.

Natural Killer Cell Therapies Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Natural Killer Cell Therapies Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Natural Killer Cell Therapies treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Natural Killer Cell Therapies market.

Download our free sample page report on Natural Killer Cell Therapies pipeline insights @ https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Natural Killer Cell Therapies Emerging Drugs

Monalizumab: Innate Pharma
NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
ALT 803: ImmunityBio
ALECSAT: CytoVac
PNK-007: Celularity

Natural Killer Cell Therapies Companies

More than 100 leading companies are actively developing therapies focused on Natural Killer (NK) Cell treatments. Among them, Innate Pharma has a drug candidate in the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 140+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Natural Killer Cell Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Natural Killer Cell Therapies Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Natural Killer Cell Therapies Therapies and Key Companies: Natural Killer Cell Therapies Clinical Trials and advancements @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Natural Killer Cell Therapies Pipeline Therapeutic Assessment
• Natural Killer Cell Therapies Assessment by Product Type
• Natural Killer Cell Therapies By Stage
• Natural Killer Cell Therapies Assessment by Route of Administration
• Natural Killer Cell Therapies Assessment by Molecule Type

Download Natural Killer Cell Therapies Sample report to know in detail about the Natural Killer Cell Therapies treatment market @ Natural Killer Cell Therapies Therapeutic Assessment @ https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Natural Killer Cell Therapies Current Treatment Patterns
4. Natural Killer Cell Therapies - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Natural Killer Cell Therapies Late-Stage Products (Phase-III)
7. Natural Killer Cell Therapies Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Natural Killer Cell Therapies Discontinued Products
13. Natural Killer Cell Therapies Product Profiles
14. Natural Killer Cell Therapies Key Companies
15. Natural Killer Cell Therapies Key Products
16. Dormant and Discontinued Products
17. Natural Killer Cell Therapies Unmet Needs
18. Natural Killer Cell Therapies Future Perspectives
19. Natural Killer Cell Therapies Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Natural Killer Cell Therapies Pipeline Reports Offerings: https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Natural Killer Cell Therapies Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, C here

News-ID: 3860439 • Views:

More Releases from DelveInsight Business Research LLP

Multiple Myeloma Market Size (7MM) was estimated to be nearly USD 21,300 million in 2023, which is expected to show positive growth by 2034, estimated DelveInsight
Multiple Myeloma Market Size (7MM) was estimated to be nearly USD 21,300 million …
DelveInsight's "Multiple Myeloma Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of multiple myeloma, historical and forecasted epidemiology as well as Multiple Myeloma therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Discover more about the multiple myeloma market in detail @ Multiple Myeloma Market Report- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Multiple Myeloma Market Report • In September
Warm Autoimmune Hemolytic Anemia Market Size (7MM) was estimated to be ~USD 300 million in 2023, which is expected to grow by 2034, estimates DelveInsight
Warm Autoimmune Hemolytic Anemia Market Size (7MM) was estimated to be ~USD 300 …
DelveInsight's "Warm Autoimmune hemolytic anemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Warm Autoimmune hemolytic anemia, historical and forecasted epidemiology as well as the Warm Autoimmune hemolytic anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To know in detail about the Warm Autoimmune hemolytic anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here
Cervical Cancer Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight
Cervical Cancer Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Inn …
DelveInsight's, "Cervical Cancer Pipeline Insights 2025" report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Cervical Cancer pipeline landscape. It covers the Cervical Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cervical Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Download DelveInsight's comprehensive Cervical Cancer Pipeline Report
Helicobacter Pylori Infection Market Size (7MM) was ~USD 2,672.5 million in 2022 and is projected to grow by 2034, estimates DelveInsight
Helicobacter Pylori Infection Market Size (7MM) was ~USD 2,672.5 million in 2022 …
(Albany, USA) DelveInsight's report, "Helicobacter Pylori Infections Market Insights, Epidemiology, and Market Forecast - 2034," delivers an in-depth analysis of the H. pylori infection market across the United States, EU5, and Japan. The study includes historical and forecasted epidemiology, current and emerging treatment patterns, market size projections from 2020-2034, and detailed drug-level market share assessments. Additionally, the report evaluates treatment pathways, major market drivers, limitations, and areas of unmet clinical

All 5 Releases


More Releases for Cell

Cell Sorting Market Accelerates as Cell Therapy, Immuno-Oncology & Single-Cell R …
The rising focus on precision medicine, immunotherapy, and advanced cell-based research is driving the global cell sorting market into a high-growth phase. With expanding applications in stem cell therapy, CAR-T manufacturing, cancer immunology, and single-cell genomics, demand for accurate, high-purity cell isolation systems is stronger than ever. This release highlights key market trends, segmentation insights, technological innovations, and the factors shaping the future of cell sorting. Download Full PDF Sample Copy
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period. The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic "Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic. Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445 Current
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939 This latest report researches the industry structure, sales, revenue,
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports. This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions. This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer. Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u Top Key Players: - Becton, Dickinson and Company Biospherix EMD Millipore Eppendorf AG Merck KGaA Sartorius AG VWR International Cell culture is a rapidly emerging